AR and prostate cancer: We note with interest that treatment of prostate cancer patients with BioResponse 3,3′- Diindolylmethane (BR-DIM) resulted in re-expression of miR-34a due to reversal of the methylation-induced silencing of the miR-34a promoter, and suppressed the expression of miR-34a target genes including the androgen receptor and Notch-1 [54].